about
[Late interruption of pregnancy due to foetal disease: is an inductive method for the generation of ethical principles applicable?].Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormoneAEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.The role of regulatory T cells in ovarian cancer.Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.Pregnancy-triggered antiphospholipid syndrome in a patient with multiple late miscarriages.Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer.Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer.Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1.Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles.Inhibin A/B in HMG or recombinant FSH ovarian stimulation with cetrorelix medication.Prognostic impact of infiltration of the vagina and/or uterus in women undergoing anterior pelvic exenteration for urothelial carcinoma of the bladder: results of a contemporary multicentre series.Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancer--Occam's razor or the "third man".Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter studyGrowth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238[Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues]Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteinsPapillary squamotransitional cell carcinoma of the vagina
P50
Q30412180-4F93B26C-E5C6-4478-8B1D-BA31FD42A6C6Q33906715-D3BADA53-579F-44E7-A62C-95F4BA7FD202Q34274245-D8811587-CAAD-46C2-9CE6-2C9072EC28D7Q34604396-DBD1772F-B520-4FF7-8169-9DF0519AE381Q34772221-41E458FA-94EC-4F2D-9015-75F90FA6F19AQ34894406-9ADEFDF9-D037-42A1-B47B-41C8C00A9896Q35629436-519FA5FC-CA8B-482A-9C02-1E080E30080AQ36739910-68BBEAD0-EFF5-4718-9D0E-64EA8969D639Q36912988-9EFAC3BD-4AE0-4EA2-A79A-9EFB3CFFEE4CQ37323454-5CB306E8-D1A0-493C-9181-678C860F3A63Q38341058-4C5AE63C-4407-4E60-9FF5-B9F1634C0C50Q38949880-2C7F3AB5-AF9A-4260-B74A-E2C33588A5A8Q38966925-15E97344-77A0-4DB2-9067-BF165EB70F4CQ39188729-729067CC-3C9D-475F-9C9B-B39BB61EDF86Q39275540-37E9CC06-F86F-414A-B7B5-F29B49376BC5Q39346919-D86DC8C7-25D4-4AD0-89B9-7253E2EA51D7Q39531156-602CEA5E-F7E1-484F-A126-3D6A2816FA09Q39952931-D30D9343-5FBD-4C6B-813B-7DA83F97DE11Q40390236-113806C8-0AA1-4F24-B8C3-E16ABA76975AQ40392702-D5EC0172-3502-4B19-92E5-1922EDDFD199Q40402230-8DE3A18B-C811-4442-9541-BD4924B492DAQ44085092-97C0944B-9055-457A-9347-60CCF1E9F970Q44577463-C847CF7F-9CAE-46B4-B8DE-5A91DE88D5D5Q48821368-668F35E1-BE1C-43C2-8E9D-E236619C3C8EQ48840034-8E721B87-C5FD-454C-9D75-5E697094E925Q51140876-06F7848B-BAE3-4175-8FB7-B8C516D354C7Q51737620-20B7054D-80E2-42CD-9A7B-D3042E583E55Q54674276-D81551D8-B7FD-4489-B6F1-C9A3453118F2Q80163377-0070E24F-9972-45CA-8484-C66922ABEAEEQ81170804-7147BB8C-DB3A-4877-9182-BA21EB50F046Q81293191-0D46EA16-8C10-470E-8178-9E742381FADFQ81562397-5C12445E-7D64-433E-9110-C5139995CB0DQ84943044-AB0E621A-83BB-4017-B76A-78D5A4278F5E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jörg B Engel
@nl
Jörg B Engel
@sl
Jörg B. Engel
@en
Jörg B. Engel
@es
type
label
Jörg B Engel
@nl
Jörg B Engel
@sl
Jörg B. Engel
@en
Jörg B. Engel
@es
prefLabel
Jörg B Engel
@nl
Jörg B Engel
@sl
Jörg B. Engel
@en
Jörg B. Engel
@es
P106
P1153
35493050400
P31
P496
0000-0002-7384-2052